Recently Featured

Pharma Rings the Changes as CEO Shake-Up Continues

March 13, 2026
Recent shifts in leadership across the pharmaceutical sector have highlighted a growing trend of CEO departures, with some executives leaving for personal reasons while others are being ousted due to disappointing company performance. This wave of changes reflects the industry’s increasing pressure to deliver results amid evolving market dynamics and regulatory scrutiny. The implications of…

Pfizer CEO Albert Bourla Critiques FDA’s CBER Leadership Under Vinay Prasad

March 12, 2026
Pfizer CEO Albert Bourla, Ph.D., has publicly criticized Dr. Vinay Prasad, the head of the FDA’s Center for Biologics Evaluation and Research (CBER), highlighting significant concerns regarding his leadership. Bourla’s remarks come at a time when the regulatory landscape for biologics and vaccines is under intense scrutiny, particularly given the ongoing challenges posed by public…

Expert Advisory Group Issues Recommendations on Paclitaxel Drug-Coated Balloons and Stents

March 12, 2026
The independent Expert Advisory Group has released new guidance regarding the use of paclitaxel drug-coated balloons (DCBs) and drug-eluting stents (DESs) for treating peripheral arterial disease. This guidance follows a thorough review of clinical evidence and safety data, reflecting ongoing concerns about potential risks associated with paclitaxel-based devices. Contextually, the recommendations arise amidst heightened scrutiny…

Europe’s pharma trade with the US remains critical despite tariff turmoil

March 12, 2026
Europe’s pharmaceutical trade with the United States continues to be a vital component of the sector, even amid ongoing tariff disputes. The US market remains a primary destination for new drugs developed in Europe, offering significant revenue opportunities that are essential for sustaining growth in the European pharma industry. As governments increasingly pivot towards establishing…

Ongoing Cases